The Biosimilars LatAm – Mexico 2022 forum’s main focus is The Collaborative Approach which is priorly aimed at harmonizing the legal frameworks that are applicable to biosimilar drugs.
The goal is to seek and strengthen all prescription and access processes of these treatments in order to help the patients in the region.
Collaborative approaches in general, require a multidisciplinary effort and therefore all sessions presented during this forum, will provide you with a wide scope of the current status and efforts that have been made towards the improvement of the public health sector in Mexico and Latin America.
- commercial strategies
- diversification of production and suppliers
- quality and integrity of biopharma products
Industry Executives from Latam
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Business Development
Program at a Glance
Collaborative: Reference Authorities' Approach Towards Regulation
Pharmacovigilance: Acting to Protect Public Health
Interchangeability: from Regulatory Consensus to Scientific Facts
The best-practices and improvement overview directly from Healthcare professionals to secure the traceability of medicaments and ability to track the patient’s medical journey. Securing the ability to reacting promptly in case any adverse-effects happen and be able to change the cure knowing exactly the root of the problem
Ensuring the Quality and Integrity of Biopharmaceutical Products
Biosimilars' Adoption Commercial Measures
Procurement and Healthcare: Biosimilars Tendering
Innovation and Competitiveness in Pharmaceuticals: Biosimilars Case Study
Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.
Full programme in the PDF Agenda
We are a vibrant science and technology company. Science is at the heart of everything we do, it drives the discoveries we make and the technologies we create. For more than 350 years, curiosity has been driving us to deliver excellence to patients and customers – and to imagine the future.
Agilent is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions.
Pall associates around the world are unified by a singular drive: to solve our customers’ biggest filtration, separation and purification challenges. And, in doing so, advance health, safety and environmentally responsible technologies.
Our industry-leading technologies and solutions are at work in countless applications, safeguarding health, protecting critical operating assets, improving product quality, and minimizing emissions and waste.
Our Life Sciences and Industrial teams bring focused expertise to a diverse range of customers across multiple industries, including biotechnology, pharmaceutical, medical, food and beverage, laboratory, microelectronics, aerospace, fuels, petrochemical, chemical, automotive and power generation .
Cytiva is a global provider of technologies and services that help advance and accelerate the development and production of therapeutic products. Promoting training, speed and efficiency for research and production workflows, allowing the delivery of innovative medicines to patients.
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2019, the company earned sales revenue of some 1.83 billion euros according to preliminary figures. At the end of 2019, more than 9,000 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
We develop alliances with pharmaceutical companies, using Terumo technology to develop, manufacture and supply solutions to injectable drug delivery challenges. We pride ourselves on offering a portfolio of products and services for the pharmaceutical industry. By anticipating trends and maintaining a constant dialogue, we provide a first class customer experience.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
UDIBI is a third-party laboratory authorized by COFEPRIS to conduct biosimilarity studies. Our experience is huge analyzing therapeutic biomolecules (recombinant hormones, cytokines, fusion proteins and monoclonal antibodies). Nowadays our capabilities have expanded to antibody engineering and development of antibody-based therapeutics. During the COVID-19 pandemic we developed products for research and diagnostic, highlighting our ELISA kit UDITEST-V2G to detect anti-SARS-CoV-2 antibodies.